NEKTAR CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Nektar Therapeutics for alleged misleading statements regarding the REZOLVE-AA trial, impacting investors who acquired Nektar securities between February 26, 2025, and December 15, 2025 [2][7]. Allegation Details - The lawsuit claims that Nektar made false and misleading statements about the enrollment process in the REZOLVE-AA trial, which did not adhere to proper protocols, potentially affecting the trial's results [7]. - It is alleged that the integrity and prospects of the REZOLVE-AA trial were overstated, leading to material misrepresentation in public statements [7]. - Following the announcement of the trial's failure to reach statistical significance on December 16, 2025, Nektar's stock price dropped by $4.14, or 7.77%, closing at $49.16 per share [7]. Next Steps - Investors who suffered losses and wish to discuss their legal rights or learn more about the claims are encouraged to contact the law firm Bragar Eagel & Squire [4].